Anti-Human RANKL

Pricing & Details

Product No.R1242
Protein
Receptor Activator of NF-κB Ligand
Formats AvailableView All
Product Type
Polyclonal Antibody
Alternate Names
CD254, TRANCE, hRANKL2, sOdf, TNF-Related Activation-Induced Cytokine [TRANCE], Osteoprotegrin Ligand [OPGL], Osteoclast Differentiation Factor [ODF], TNFSF11
Applications
WB
Prod No.
Size
Price
Avail.
Qty
Add to cart
R1242-20ug
20 µg
$195.00
In stock
Max:
Min: 1
Step: 1
R1242-0.1 mg
0.1 mg
$397.00
In stock
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Data

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Rabbit
Immunogen
PN:R1243
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti-Human soluble Receptor Activator of NF-κB Ligand (sRANK Ligand) recognizes Human, Mouse and Rat sRANK Ligand. This polyclonal antibody was purified using affinity chromatography.
Background
RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine.1 RANKL is essential for osteoclast formation, activation, and survival.2 RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation.3 RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.4

Antigen Details

References & Citations

1. Takayanagi, H. et al. (2003) Arthritis Res Ther. 5: 20
2. Kostenuik, PJ. et al. (2005) Endocrinology 146: 3235
3. Holven, KB. et al. (2009) Stroke 40: 241
4. Penninger, JM. et al. (2008) Ann N Y Acad Sci. 1143: 123
General Western Blot Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok